A Multicentre, Phase 2 Clinical Trial to Establish the Efficacy and Safety of Repeat Dosing of Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase (eNOS) in Patients With Pulmonary Arterial Hypertension (PAH) on Top of Conventional Treatments
Principal Investigator
John SwistonOverview
Study Start/End
Jan 14, 2019 to Apr 30, 2021Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Mami Okada, Research CoordinatorPhone
604-875-4111 ext.69831Email Address
mami.okada@vch.caPurpose of Study
The purpose of this study is to establish the efficacy and safety of repeated monthly dosing of endothelial progenitor cells (EPCs) transfected with human endothelial NO-synthase (eNOS) in patients with symptomatic severe pulmonary arterial hypertension (PAH) on available PAH-targeted medical therapy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.